Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - itraconazole - oral capsule - 100mg

Estados Unidos - inglês - NLM (National Library of Medicine)

carilion materials management - itraconazole (unii: 304nug5gf4) (itraconazole - unii:304nug5gf4) - itraconazole 100 mg - itraconazole capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: - blastomycosis, pulmonary and extrapulmonary - histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and - aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin b therapy. specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. itraconazole capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: - onychomycosis of the toenail, with or without fingernail involvement

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

beacon pharmaceuticals ltd - itraconazole - oral solution - 10 mg/ml - itraconazole

Malta - inglês - Medicines Authority

syri limited - itraconazole - oral solution - itraconazole 10 mg - antimycotics for systemic use

Malta - inglês - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - itraconazole - hard capsule - itraconazole 100 mg - antimycotics for systemic use

Malta - inglês - Medicines Authority

syri pharma limited floor 0 1 wml, 1 windmill lane dublin 2, d02 f206, ireland - itraconazole - oral solution - itraconazole 10 mg - antimycotics for systemic use

Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

crescent pharma ltd - itraconazole - oral capsule - 100mg

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

athlone laboratories ltd - itraconazole - oral solution - 10 milligram(s)/millilitre - triazole derivatives; itraconazole

Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - itraconazole - oral capsule - 100mg

Estados Unidos - inglês - NLM (National Library of Medicine)

patriot pharmaceuticals, llc - itraconazole (unii: 304nug5gf4) (itraconazole - unii:304nug5gf4) - itraconazole oral solution is indicated for the treatment of oropharyngeal and esophageal candidiasis. (see clinical pharmacology: special populations, warnings, and adverse reactions: post-marketing experiencefor more information.) itraconazole oral solution should not be administered to patients with evidence of ventricular dysfunction such as congestive heart failure (chf) or a history of chf except for the treatment of life-threatening or other serious infections. (see boxed warning, warnings, precautions: drug interactions-calcium channel blockers, adverse reactions: post-marketing experience, and clinical pharmacology: special populations.) coadministration of a number of cyp3a4 substrates are contraindicated with itraconazole oral solution. plasma concentrations increase for the following drugs: levaceytlmethadol (levomethadyl), methadone, disopyramide, dofetilide, dronedarone, quinidine, isavuconazole, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), er